Immunotherapy in metastatic non-small cell lung cancer: EPSILoN as a prognostic score
M. Alves Valente (Porto, Portugal), M. Serino (Porto, Portugal), C. Freitas (Porto, Portugal), M. Martins (Porto, Portugal), P. Ferreira (Porto, Portugal), C. Cardoso (Porto, Portugal), C. Sousa (Porto, Portugal), V. Santos (Porto, Portugal), D. Araújo (Porto, Portugal), H. Novais-Bastos (Porto, Portugal), A. Magalhães (Porto, Portugal), H. Queiroga (Porto, Portugal), G. Fernandes (Porto, Portugal), V. Hespanhol (Porto, Portugal)
Source: International Congress 2022 – Lung cancer patient pathways
Session: Lung cancer patient pathways
Session type: Thematic Poster
Number: 2641
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Alves Valente (Porto, Portugal), M. Serino (Porto, Portugal), C. Freitas (Porto, Portugal), M. Martins (Porto, Portugal), P. Ferreira (Porto, Portugal), C. Cardoso (Porto, Portugal), C. Sousa (Porto, Portugal), V. Santos (Porto, Portugal), D. Araújo (Porto, Portugal), H. Novais-Bastos (Porto, Portugal), A. Magalhães (Porto, Portugal), H. Queiroga (Porto, Portugal), G. Fernandes (Porto, Portugal), V. Hespanhol (Porto, Portugal). Immunotherapy in metastatic non-small cell lung cancer: EPSILoN as a prognostic score. 2641
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|